Q2 EPS Estimate for Eton Pharmaceuticals Lifted by Analyst

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Research analysts at HC Wainwright lifted their Q2 2026 earnings estimates for shares of Eton Pharmaceuticals in a note issued to investors on Monday, March 2nd. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of $0.28 per share for the quarter, up from their prior estimate of $0.27. HC Wainwright has a “Buy” rating and a $37.00 price objective on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.14) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q3 2026 earnings at $0.33 EPS, Q4 2026 earnings at $0.37 EPS, FY2026 earnings at $1.18 EPS, FY2028 earnings at $2.58 EPS and FY2029 earnings at $3.45 EPS.

Other equities research analysts also recently issued research reports about the company. Craig Hallum upped their price objective on Eton Pharmaceuticals from $29.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday. Zacks Research raised Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. Wall Street Zen downgraded shares of Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, December 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a report on Thursday, January 22nd. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $31.00.

Eton Pharmaceuticals Stock Performance

ETON stock opened at $17.24 on Thursday. Eton Pharmaceuticals has a twelve month low of $11.09 and a twelve month high of $23.00. The company has a quick ratio of 1.25, a current ratio of 1.63 and a debt-to-equity ratio of 1.19. The company has a market cap of $462.38 million, a P/E ratio of -68.96 and a beta of 1.19. The business’s fifty day moving average is $16.23 and its 200-day moving average is $17.24.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of ETON. Caitong International Asset Management Co. Ltd acquired a new stake in Eton Pharmaceuticals during the 4th quarter worth approximately $50,000. Invesco Ltd. increased its position in shares of Eton Pharmaceuticals by 46.1% during the fourth quarter. Invesco Ltd. now owns 19,691 shares of the company’s stock worth $333,000 after acquiring an additional 6,213 shares in the last quarter. XTX Topco Ltd increased its position in shares of Eton Pharmaceuticals by 33.3% during the fourth quarter. XTX Topco Ltd now owns 32,527 shares of the company’s stock worth $550,000 after acquiring an additional 8,128 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Eton Pharmaceuticals by 400.1% during the fourth quarter. Millennium Management LLC now owns 79,331 shares of the company’s stock worth $1,341,000 after acquiring an additional 63,469 shares during the period. Finally, Jump Financial LLC acquired a new stake in shares of Eton Pharmaceuticals in the 4th quarter valued at about $178,000. 27.86% of the stock is currently owned by institutional investors and hedge funds.

More Eton Pharmaceuticals News

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its price target to $37 and lifted multiple quarterly and multi‑year EPS forecasts (including FY2026–FY2029 and longer‑term outlook), maintaining a Buy rating — a bullish signal for longer‑term revenue/profit expectations. HC Wainwright Boosts Eton Pharmaceuticals (NASDAQ:ETON) Price Target to $37.00
• Neutral Sentiment: Reported short‑interest data for early March shows effectively zero short interest (data appears inconsistent/placeholder), so short squeezes or heavy short selling are not an immediate explanatory factor for today’s move.
• Neutral Sentiment: Trading context: intraday volume was above average and the stock is near its 200‑day moving average — this can amplify moves on news or positioning changes as investors adjust exposure.
• Negative Sentiment: HC Wainwright trimmed its Q1 2026 EPS estimate (from $0.23 to $0.20), a near‑term downgrade that could explain some downward pressure despite the longer‑term upgrades. Eton Pharmaceuticals on MarketBeat

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.